Exhibit 10.1CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.AMENDMENT NO. 2TO MANUFACTURING AND SUPPLY AGREEMENTTHIS AMENDMENT NO. 2 (this “Amendment”) to the Manufacturing and Supply Agreement dated as of December 8, 2009 (asamended by an amendment agreement dated 31 December 2013) (the “Existing Agreement”), by and between Columbia Laboratories,(Bermuda) Ltd., a limited company existing and organised under the laws of Bermuda, having a place of business at Canon’s Court, 22Victoria Street, Hamilton HM12, Bermuda (“Columbia”), and Fleet Laboratories Limited, a limited private company existing andorganised under the laws of England, having a place of business at 94 Rickmansworth Road, Watford Herts, WD18 7JJ, United Kingdom(“Fleet”) is entered into on 2018 (the “Effective Date”).WHEREAS, Columbia and Fleet entered into the Existing Agreement pursuant to which Fleet has agreed to manufacture and supply toColumbia, and Columbia has agreed to purchase, certain Products; andWHEREAS, Columbia and Fleet wish to amend the Existing Agreement in accordance with the terms of this Amendment.NOW THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which ishereby acknowledged, Columbia and Fleet agree as follows:GeneralCapitalised terms used but not defined in this Amendment shall have the same meanings ascribed to such terms in the ExistingAgreement. The following amendments to the Existing Agreement shall have effect on and from the Effective Date.1.The following definitions shall be added to Section 1 of the Existing Agreement:““Ares Agreement” means the supply agreement entered into between Columbia and Ares Trading S.A. (a subsidiary ofMerck Serono S.A.) dated 7 January 2018.”“GDP” means the EU guidelines for current Good Distribution Practice guidelines 2013/C 343/01 as amended.”2.The definition of “batch” in Section 1 of the Existing Agreement shall be deleted in its entirety and replaced with the following:““Batch” means a quantity of [] kilograms of material (or such other quantity as the Parties mayagree in writing from time to time) produced in a process or series of processes that is expected to behomogeneous within specified limits.”3.The following shall be added to Section 2.1 of the Existing Agreement (Regulatory Requirements) as a new Section 2.1 (d):“2.1 (d)Subject to the prior written consent of Columbia (such consent not to be unreasonablywithheld, delayed or conditioned), Fleet may subcontract all or part of the activities to be performed byit under this Agreement to any subcontractor provided that the subcontracting of any activities shallnot relieve Fleet of, and Fleet shall remain solely liable for, its obligations under this Agreement.Columbia may subcontract all or any part of the activities performed by it under this Agreement to anysubcontractor without the consent of Fleet.”1CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.4.The following new Sections 2.2 (b), 2.2 (c) and 2.2 (d) shall be added to Section 2.2 of the Existing Agreement (RegulatoryRequirements):“2.2 (b) Compliance with Brazilian Regulatory Authorities Regulations. Fleet hereby warrantsthat the facilities where the Product is manufactured complies in full with the relevant standardsstipulated by the Brazil National Health Surveillance Agency (“ANVISA”) and undertakes to ensure thefacilities will continue to do so throughout the Term.2.2 (c)Compliance with Regulatory Approvals. To the extent required for regulatorypurposes, Fleet grants to Columbia the right to refer to, and to grant any purchasers of Columbia’sproducts containing the Product the right to refer to Fleet’s batch manufacturing records relating to theProduct. Fleet undertakes to notify Columbia and to provide Columbia with specific details of anychanges to be made to the batch manufacturing records and any other filings made by Fleet with theRegulatory Authorities to the extent that they relate to the Product.2.2 (d)Material Change in Manufacturing Process. Fleet shall provide reasonable notice toColumbia and shall consult with Columbia before Fleet makes any material change in anymanufacturing process for the Product.”5.Section 2.3 (c) of the Existing Agreement (Raw Materials) shall be deleted and replaced by the following:2.3 (c)Raw Materials. Fleet shall be responsible for ordering [] Raw Materials other than[] and the [] (which shall be provided by Columbia), as required to support Fleet’s obligationsunder this Agreement. All right, title and interest in and to the Raw Materials provided by Columbia(including but not limited to the [] and the []) shall remain with Columbia at all times. Fleet shallensure that all Raw Materials are released for use at least [] prior to their use in manufacturing theProduct. Fleet shall maintain sufficient stocks of Raw Materials to meet its manufacturing and supplyobligations to, and as set out in any Production Schedule by, Columbia; provided however that Fleetshall have a retest date in accordance with the relevant supplier’s written instructions (or where none,Fleet’s SOPs, which Fleet shall provide to Columbia upon request) for Raw Materials. Raw Materialsshall not be used beyond their expiration date as provided by the Raw Materials supplier.(i)[] costs of Raw Materials shall be included in the Purchase Price. Fleet shallbe responsible for [] of Raw Materials hereunder which Fleet supplies. For theavoidance of doubt, Columbia shall be responsible for all such costs only inrespect of [] and [] provided by Columbia to Fleet. Fleet shall not use anyRaw Materials purchased directly by Columbia except for the manufacture ofProduct hereunder. Columbia will be responsible for all retesting costs associatedwith the Raw Materials supplied by Columbia.(ii)Fleet shall notify Columbia of any Raw Materials that do not meet thespecifications of the Raw Materials, and shall provide Columbia with full detailswithin twenty-four (24) hours of completion of the investigation, but not more thantwenty (20) business days from identification of the non-conformity with thespecifications.2CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.6.A new Section 2.3 (n) shall be inserted into the Existing Agreement as follows:“2.3 (n)KPIs. As soon as practicable following the Effective Date the Parties shall agree ingood faith key performance indicators the Supplier will agree to achieve when supplying the Productsand such key performance indicators will be set out in an amendment agreed by the Parties to thisAgreement.”7.A new Section 3A shall be inserted into the Existing Agreement as follows:“3A Machinery and Equipment3A.1Columbia has provided Fleet with the machinery, equipment and materials listed inExhibit B, which Fleet uses to manufacture Products (“Columbia Equipment”). Any additionalmachinery, equipment and materials provided by Columbia to Fleet during the Term shall be ColumbiaEquipment unless otherwise agreed in writing by both Parties. During the Term, Columbia shall reviewand update Exhibit B in December of each year to include any additional machinery, equipment andmaterials provided to Fleet.3A.2The Parties confirm that Columbia owns title to all Columbia Equipment and thatColumbia shall be regarded as the owner of the Columbia Equipment notwithstanding that theColumbia Equipment shall be retained at Fleet’s premises. Fleet shall not do or permit or causeanything to be done whereby Columbia’s rights in and title to the Columbia Equipment are or maybecome prejudiced including, without limitation, by ensuring that Columbia Equipment are clearlymarked as the property of Columbia. No item of Columbia Equipment may be moved from Fleet’spremises without the prior written consent of Columbia.3A.3Fleet shall not use the Columbia Equipment for any purpose other than supplyingColumbia with the Product in accordance with the terms of this Agreement without Columbia’s priorwritten consent.3A.4Fleet will at all times ensure that the Columbia Equipment meets and is operated andmaintained in accordance with Applicable Laws and cGMP and GDP.3A.5 Fleet shall maintain the Columbia Equipment, the reasonable costs of which shall beagreed by the Parties (acting reasonably) and paid by Columbia, and:(a)maintenance shall be carried out to at least the standards adopted in respect of Fleet’sother machinery and equipment used by it at its premises and Fleet shall not prioritize themaintenance of its own equipment above that of the Columbia Equipment;(b)Fleet shall at all times ensure that it has sufficient trained and competent maintenancepersonnel available for such maintenance;(c)during the Term, on or before 1 January of each year, Fleet shall prepare and deliver toColumbia:(i)a maintenance plan setting out the maintenance activities to be performed byFleet in respect of the Columbia Equipment for the following year; and3CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.(ii)a maintenance report confirming that each of the maintenance activities set outin the previous year’s maintenance plan have been carried out;(d)Columbia shall have the right to request a maintenance report in respect of any of theColumbia Equipment at any time during the Term which Fleet shall provide to Columbiawithin twenty-eight (28) days;(e)Fleet shall inform Columbia of the need for any overhauls, replacements and repairs andshall perform all such overhauls, replacements and repairs as reasonably instructed byColumbia (the reasonable agreed costs of which shall be borne by Columbia); and(f)if an overhaul of the Columbia Equipment is required, Fleet shall provide reasonable noticeto Columbia and shall manufacture adequate stocks of Product in advance to ensurecontinuity of supply in accordance with orders placed by Columbia pursuant to the termsof this Agreement.3A.6 Fleet shall keep the Columbia Equipment safe and in good working order and shall takeall reasonable steps to ensure that the Columbia Equipment does not become contaminated orcorroded.3A.7 Fleet shall mark each individual unit of the Columbia Equipment in a conspicuousmanner to indicate that such machinery and equipment is owned by Columbia.3A.8Fleet shall keep the Columbia Equipment free and clear of any lien, charge orencumbrance and Fleet shall obtain and deliver to Columbia a waiver of any of the foregoing in a formreasonably acceptable to Columbia.3A.9Columbia shall not be liable for any loss or damage due to the negligence or wilfulmisconduct of Fleet, its Affiliates, employees, contractors or representatives. In the event of any lossor damage of any item of the Columbia Equipment due to the negligence or wilful misconduct(including negligence or intentional misconduct in relation to the operation, inspection or maintenanceof the Columbia Equipment) of Fleet, its Affiliates, employees, contractors or representatives, Fleetshall repair or replace such items of Columbia Equipment, at Fleet’s sole cost and expense, promptlytaking into account the quantities of stock held by Fleet at the time of such loss or damage.”8.Section 3.1 of the Existing Agreement (Production Schedules) shall be deleted and replaced by the following:“3.1 Production Forecasts(a)Production Schedule. Each [], before the [], during the Term Columbia shall prepareand provide Fleet with a written Production Schedule of its requirements for Product (each, a"Production Schedule") for the following []. The amounts set forth for the [] in each ProductionSchedule shall constitute a firm purchase order and shall be binding upon Columbia (each a"Purchase Order") unless otherwise agreed in writing by both parties. The amounts set forth for thefollowing [] shall constitute Columbias non-binding, good faith estimate of the Product requirementsof Columbia for such periods. Fleet shall manufacture, supply and deliver to4CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Columbia all quantities of Product as Columbia orders in accordance with this Section 3.1. All right,title and interest in and to the Product shall remain with Columbia at all times. Fleet shall ensure thatit has sufficient experienced production staff available to meet the requirements set out in eachProduction Schedule and at a minimum, to meet the expected non-binding forecast set out below:[][][][][][]N u m b e r o fbatches[][][][][][](b) Non-Active Product Orders. From time to time during the Term, Columbia may provide Fleet with apurchase order for a batch of Product that does not contain any active pharmaceutical ingredientprovided that such purchase order is received at least ninety (90) days prior to the required deliverydate. The batch size for any Product ordered pursuant to this Section 3.1 (b) shall be set out in therelevant purchase order. All provisions of this Agreement that relate to Products shall apply equally toany Products that do not contain any active pharmaceutical ingredient.”9.Section 3.3 (a) of the Existing Agreement (Delivery) shall be deleted and replaced by the following:“3.3 (a)Delivery. All Product supplied under this Agreement shall be delivered EXW Fleet’sWatford, UK facility. All risk of loss in the Product shall pass to Columbia upon receipt of the Productat Fleet’s facility by the carrier designated by Columbia. The weights, tariffs and tests affixed byFleet’s invoice shall govern unless established to be incorrect. Claims relating to quantity, weight andloss or damage to any Product sold under this Agreement shall be waived by Columbia unless madewithin [] of receipt of Product by Columbia.”10.Section 4.1 of the Existing Agreement (Audits) shall be deleted and replaced by the following:“4.1 Audits. Columbia QA, any other person appointed by Columbia, Columbia’s customer,and/or any Regulatory Authority may conduct inspections and audits of Fleet’s manufacturing facility,Columbia Equipment, quality control laboratories, and other quality systems relating to themanufacture and storage of the Product according to Columbias reasonable procedures uponreasonable prior written notice, during normal business hours, provided, however, that Columbia QA,any other person appointed by Columbia and/or any Regulatory Authority may conduct a “For Cause”audit during normal business hours upon three (3) business days prior written notice to Fleet. Anysuch audit undertaken by Columbia QA or any other person appointed by Columbia shall be atColumbia’s sole cost and expense. Columbia or any other person appointed by Columbia shall havethe right, in connection with any such audit, to inspect and obtain copies of any records or otherdocuments and materials associated with or related to the manufacture of the Product. Fleet shallpromptly notify Columbia of any proposed inspections by any governmental authority of the facilities atwhich Product is manufactured in sufficient time for Columbia to attend such inspection.”11.Sections 5.1 (Price) and 5.2 (Invoicing) of the Existing Agreement shall be deleted and replaced by the following:5CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.“5.1 Price. During the Term, the purchase price for each Batch purchased by Columbia fromFleet in any [] shall be determined in accordance with Part 1 of Exhibit A and the pricing model setout in Part 2 of Exhibit A attached hereto, as may be amended from time to time in accordance withthe provisions of this Section 5.1. The Parties shall agree the applicable purchase price for each []in accordance with Part 1 of Exhibit A (as may be amended from time to time in accordance with thisSection 5.1) and the production forecasts received by Fleet pursuant to Section 3.1. []. Anyadjustments as set out in paragraphs (a), (b) and (c) below and any consequent adjustments to thevolume discount model set out in Part 1 of Exhibit A and/or the pricing model set out in Part 2 ofExhibit A shall be agreed in writing by both Parties and shall take effect from 1 January the followingcalendar year. Exhibit A may be amended by the mutual written agreement of both parties as follows:(a)the [] of Exhibit A shall only be amended to reflect the change in rate of the ConsumerPrice Index as published by the UK Office of National Statistics all item data series D7BT(the “CPI”). By way of example, if on 1 November in a calendar year during the Term, theCPI shows that there has been an increase in prices compared with the same index on 1November the previous year [], then [] in the model as of 1 January in the following year[] of the CPI increase as recorded on 1 November, [].(b)the [] of Exhibit A shall only be amended to reflect [] of the change in rate of the CPI.By way of example, if on 1 November in a calendar year during the Term, the CPI shows thatthere has been an increase in prices compared with the same index on 1 November theprevious year [], then [] in the model as of 1 January in the following year [] of theCPI increase as recorded on 1 November, i.e. by [].(c)the [] of Exhibit A shall only be amended to reflect any [] changes to the cost of any ofthe [] set out in Part 4 of Exhibit A. If at any other time during a calendar year the []when compared with [], Fleet shall have the right to amend the [] for any future invoicesby providing Columbia with at least three (3) months’ prior written notice.Except as otherwise set out in Section 5.1 (c), the first period during which any adjustment set out inSection 5.1 (a), (b) or (c) above will be calculated shall be [], with the adjusted costs to be appliedto the pricing model in Exhibit A for the calendar year commencing []. Fleet shall provide Columbiawith access to all books and records necessary to verify any changes to the purchase price.5.2Invoicing. Upon delivery of Product to Columbia, Fleet shall submit invoices therefor toColumbia. Columbia shall pay each invoice in full within [] after the date of receipt by Columbia ofsuch invoice, which shall be issued no earlier than the date on which the Product is delivered to thecarrier by Fleet. All payments shall be made in pounds sterling. In the event that any actual volume ofProduct purchased by Juniper in any calendar year means that a different purchase price should haveapplied to such volume of Product purchased in that calendar year (as calculated in accordance withthe pricing model set out in Exhibit A), Fleet shall notify Juniper in writing of such pricing differentialand shall apply a proportionate credit or debit (as applicable) to any invoices raised for the subsequentcalendar year. Upon the expiration or earlier termination of this Agreement,6CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Fleet shall determine the applicable purchase price for that calendar year and shall notify Juniper inwriting of any underpayment or overpayment within [] of expiration or termination (as applicable). Inthe event of any underpayment by Juniper, Juniper shall pay to Fleet an amount equal to the amountof any such underpayment within [] of receipt by Juniper of such written notice. In the event of anyoverpayment by Juniper, Fleet shall pay to Juniper an amount equal to the amount of any overpaymentwithin [] of receipt by Juniper of such written notice. Fleet shall provide Columbia with access to allbooks and records necessary to verify any changes to the purchase price and any underpayment oroverpayment.”12.Section 8 of the Existing Agreement (Insurance) shall be deleted and replaced by the following:“Fleet and Columbia shall maintain comprehensive general liability insurance, including product liabilityinsurance against claims regarding the manufacture of Product under this Agreement and sufficientcover to meet its liabilities under this Agreement in respect of the Columbia Equipment, with insurershaving an AM Best rating within the top 2 categories at the time (at the date of this Agreement knownas “superior” or “excellent”) or reasonably comparable coverage, in such amounts as it customarilymaintains for similar products and activities, but in no event less than [] per individual claim and []in the aggregate. Each party shall maintain such insurance during the Term and thereafter for so longas it customarily maintains insurance for itself for similar products and activities (but in no event lessthan [] following termination or expiration).”13.Section 10.1 (a) of the Existing Agreement (Fleet’s Indemnity Obligations) shall be deleted and replaced by the following:“10.1(a)Fleet’s Indemnity Obligations. Fleet shall defend, indemnify and hold harmlessColumbia, its Affiliates and their respective successors and permitted assigns (and the respectiveofficers, directors, stockholders, partners and employees of each) from and against any and all lossesliabilities, claims, actions, proceedings, damages and expenses (including, without limitation,reasonable attorneys and professional fees and disbursements and expenses of litigation, arbitrationor investigation) ("Damages") relating to or arising from (i) any breach by Fleet or its Affiliates of itsrepresentations, warranties, covenants, agreements or obligations under this Agreement, includingwithout limitation, the failure of Fleet to timely deliver all Product ordered or the failure of the Productto meet the Fleet Warranty and/or Product Specifications or the failure of Fleet to manufacture orwarehouse the Product in accordance with the Product Specifications and Applicable Law (includingthose relating to cGMP); and (ii) any claims of infringement or misappropriation with respect to themanufacture of the Product, except to the extent such claim of infringement relates to the use of theIntellectual Property; and (iii) any personal injury or property damage to the extent that the injury ordamage is the direct result of a failure by Fleet or its Affiliates or subcontractors to manufacture,package, or label the Product in accordance with the Specifications, GMP or Applicable Law.”14.Section 10.1 (b) of the Existing Agreement (Columbia’s Indemnity Obligations) shall be deleted and replaced by the following:“10.1 (b)Columbia’s Indemnity Obligations. Columbia shall defend, indemnify and holdharmless Fleet and its Affiliates, and their respective successors and permitted assigns (and therespective officers, directors,7CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.stockholders, partners and employees of each) from and against any and all Damages arising out of (i)the handling, possession, use, marketing, distribution or sale of any Product and finishedpharmaceutical product containing a Product by Columbia or any of its distributors or agents afterFleets delivery of the Product to Columbia (except to the extent such claims arise out of thecircumstances described in Section 10.1(a) or Fleet’s negligence or wilful misconduct); (ii) productliability claims, including, wrongful death, resulting from the use of a finished pharmaceutical productcontaining a Product (except to the extent such claims arise out of the circumstances described inSection 10.1(a) or Fleet’s negligence or wilful misconduct); (iii) any breach by Columbia of itsrepresentations, warranties, covenants, agreements or obligations under this Agreement (except to theextent any such breach is due to the negligence, breach or wilful misconduct of Fleet); and (iv) anyclaims of infringement or misappropriation relating to the Intellectual Property.”15.Sections 11.1 to 11.3 of the Existing Agreement (Confidentiality and Public Disclosure) shall be deleted and replaced by thefollowing:“11.1Confidentiality. Each party will treat as confidential the ConfidentialInformation of the other party and will take all necessary precautions to assure the confidentiality ofsuch Confidential Information. Each party agrees to return to the other party upon the expiration ortermination of this Agreement all Confidential Information acquired from such other party, except as tosuch information it may be required to retain under Applicable Law, and except for one copy of suchinformation to be retained by such partys legal counsel. Neither party shall, during the period of thisAgreement nor for five (5) years thereafter, without the other partys express prior written consent,other than as provided under this Agreement, use or disclose any such Confidential Information for anypurpose other than to carry out its obligations hereunder. Each Party shall guard such ConfidentialInformation using the same degree of care as it normally uses to guard its own confidential,proprietary information of like importance, but in any event no less than reasonable care.11.2 Permitted Disclosures. Notwithstanding the obligations ofconfidentiality and non-use set out in Section 11.1, a Receiving Party may:(a)disclose Confidential Information to a regulatory authority as reasonably necessary toobtain registration in a particular jurisdiction;(b)disclose Confidential Information to the extent such disclosure is reasonablynecessary to comply with the order of a court or is required to comply with anyApplicable Law or other regulation, directive, instruction, direction or rule of anyregulatory authority having jurisdiction over any activity under this Agreement,including to the extent such disclosure is required in publicly filed financialstatements or other public statements under rules governing a stock exchange onwhich securities issued by either party may be listed; provided, to the extentpossible, such party shall (i) notify the other party of the existence, terms andcircumstances surrounding such a requirement; (ii) consult with the other party on theadvisability of taking legally available steps to resist or narrow such requirement; (iii)provide the other party with a copy of the proposed text of such statements ordisclosure ten (10) business days in advance of the date on which the disclosure is tobe made to enable the other party to8CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.review and provide comments, unless a shorter review time is agreed; and (iv)exercise its commercially reasonable efforts to obtain an order or other reliableassurance that confidential treatment will be accorded to such portion of theConfidential Information required to be disclosed;(c)disclose Confidential Information on a strict need to know basis to such ReceivingParty’s licensee’s, employees, Affiliates, contractors (including clinical researchers),distributors, agents and consultants as such Receiving Party reasonably determinesis necessary to receive the benefit of the licenses and rights granted or available to itunder this Agreement or to fulfil its obligations pursuant to this Agreement; provided,however, any such person is bound in writing to observe confidentiality provisions atleast as strict as those of this Agreement;(d)disclose Confidential Information: (i) to its actual or potential investment bankers; (ii)to existing and potential investors in connection with an offering or placement ofsecurities for purposes of obtaining financing for its business and to actual andprospective lenders for the purpose of obtaining financing for its business; and (iii) to abona fide potential acquirer or merger partner for the purposes of evaluating enteringinto a merger or acquisition, provided, however, any such persons must be obligatedto substantially the same extent as set forth in Section 11.1 to hold in confidence andnot make use of such Confidential Information for any purpose other than thosepermitted by this Agreement; and(e)disclose Confidential Information to its legal advisers for the purpose of seekingadvice.11.3 Public Announcements. Except for such disclosure as is permittedunder Section 11.2 or as required by Applicable Law or the requirements of a national securitiesexchange or another similar regulatory body, no announcement, news release, public statement,publication, or presentation relating to this Agreement, the subject matter hereof or either party’sperformance hereunder will be made without the other party’s prior written approval.16.Section 12.1 of the Existing Agreement (Term) shall be deleted and replaced by the following:“12.1 Term. Unless terminated earlier pursuant to Section 12.2 below, theinitial term of this Agreement shall expire on 31 December 2024 (the “Initial Term”) unless the Partiesmutually agree in writing any extension to the Initial Term. Upon termination of this Agreement, Fleetagrees to perform its obligations under this Agreement until the earlier of [].”17.Section 12.2 (b) of the Existing Agreement, regarding termination of the Existing Agreement by Columbia, shall be deletedand replaced by the following:“12.2 (b)Columbia shall have the right to terminate this Agreement upon [] notice to Fleet inthe event:(i)Fleet fails to maintain its authorizations under Applicable law to manufacture the product,including without limitation those from MHRA;9CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.(ii)a Change of Control Event with respect to Fleet occurs;(iii)Fleet cannot supply product at a Competitive Price; or(iv)the Ares Agreement is terminated.”18.Section 12.3 (b) of the Existing Agreement (Effect of Expiration and Termination) shall be deleted and replaced by thefollowing:“12.3 (b)Expiration or termination of this Agreement shall not relieve the parties of anyobligation accruing prior to such expiration or termination. The provisions of Sections 1 (Definitions),3A.2, 3A.3 and 3A.8 (Machinery and Equipment), 4.1 (Audits), 5.2 (Invoicing), 7 (Representations andWarranties), 8 (Insurance), 9 (Adverse Events; Recalls), 10 (Indemnification; Limitation of Liability),11.1 (Confidentiality and Public Disclosure), 12 (Term and Termination) and 13 (General Provisions)shall survive any expiration or termination of this Agreement.”19.Section 12.3 (c) of the Existing Agreement (Effect of Expiration and Termination) shall be deleted and replaced by thefollowing:“12.3 (c)If Columbia terminates this Agreement under Section 12.2 (b)(ii) or (iii), Columbiashall reimburse Fleet for [] purchased by Fleet under this Agreement in the period of [] prior tothe date of termination that are only used by Fleet in the manufacture of the Products.”20.The following new Sections 12.3 (d) and 12.3 (e) shall be added to Section 12.3 of the Existing Agreement (Effect ofExpiration and Termination):“12.3 (d) If Columbia terminates this Agreement under Section 12.2 (a)(i) in the case of Fleet’s breachof this Agreement, under Section 12.2 (a)(ii) in the case of Fleet’s insolvency or other financial difficultyunder that section, or under Section 12.2 (b) or 12.2 (c), subject to the reimbursement of Fleet’sreasonable costs and expenses, Fleet shall provide such assistance as Columbia may reasonablyrequest to Columbia and, if relevant, any third party supplier, to ensure that Columbia (or any of itsAffiliates) and, if relevant, any third party supplier has sufficient access to Fleet’s facilities andequipment, and to the Columbia Equipment, in order to continue to manufacture the Product. Fleetshall continue to supply the Product under the then current terms and conditions of this Agreement foras long as is necessary to enable the transfer of the manufacture of the Product to Columbia or a thirdparty supplier in accordance with Section 12.3 (e).12.3 (e) Fleet shall provide such assistance as Columbia may reasonably request to ensure theorderly transfer of the manufacture of the Product to any alternative manufacturer. If requested byColumbia, Fleet shall transfer to Columbia or the alternative manufacturer all technology and know-hownecessary or useful to give Columbia or the alternative manufacturer the capability of manufacturingthe Product. Fleet shall communicate such technology to Columbia or the alternative manufacturerpromptly, effectively and economically, so that Columbia or the alternative manufacturer can undertakethe manufacture of the Product and continue the sale of the Product without interruption. Columbiaundertakes to reimburse Fleet for its reasonable costs of providing such assistance and to pay toFleet an amount for all inventory of Raw Materials and work in progress of Products and partcompleted Products used to provide such assistance.”10CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.21.Section 13.1 of the Existing Agreement (Notices) shall be amended such that any notice sent to Columbia under thisAgreement shall not be copied to Columbia Laboratories, Inc. at 4 Liberty Square Fourth Floor, Boston, MA 02109 but shallinstead be copied to the following address:“Juniper Pharmaceuticals UK Limited8 Orchard PlaceNottingham Business ParkNottingham, EnglandNG8 6PXAttention: Chief Operating Officer”22.Section 13.2 of the Existing Agreement (Assignment) shall be deleted and replaced by the following:“13.2Assignment. Neither party shall, without the prior written consent (not to be unreasonablywithheld or delayed) of the other party having been obtained, assign or transfer this Agreement to anyperson or entity, in whole or in part (and any attempt to do so shall be void), provided that, each partymay assign or transfer this Agreement without such consent to any Affiliate or to any successor bymerger of such party, or upon a sale or other transfer of all or substantially all of such partys assets orbusiness to which the subject matter of this Agreement pertains, provided that the acquirer of thebusiness confirms to the Supplier in writing its agreement to be bound by all of the terms andconditions of this Agreement and that the assignor shall remain liable for the obligations hereunder.Notwithstanding the foregoing, it shall not be deemed unreasonable for Columbia to withhold consent,to any proposed or attempted assignment (including by merger or sale) by Fleet to a party which isnot an Affiliate, if Columbia is not reasonably satisfied that the assignee possesses the management,finances, personnel, capabilities and facilities to perform fully the obligations of Fleet hereunder. All ofthe terms and provisions of this Agreement shall be binding upon and inure to the benefit of and beenforceable by the parties hereto and their respective successors and permitted assigns.”23.Section 13.12 of the Existing Agreement (Technical Agreement) shall be deleted and replaced by the following:“13.12Technical Agreement. Columbia and Fleet are parties to a certain technical agreement dated18 March 2015 (as such agreement may be amended in accordance with its terms fromtime to time) (the “Technical Agreement”), the terms of which outline the responsibilitiesof Columbia and Fleet with respect to assuring the quality of the Product. Columbia andFleet acknowledge and agree that in the event the terms of this Agreement and theTechnical Agreement conflict or are inconsistent, the terms of this Agreement shall prevailover the terms of the Technical Agreement; provided however, that to the extent possible, theterms of both the Technical Agreement and this Agreement shall be read and considered toeffect the intent of the parties.”24.The following new Section 13.13 shall be added to Section 13 of the Existing Agreement (General Provisions):“13.13Anti-Bribery.(a)The parties agree:11CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.(i)to comply with all Applicable Law, statutes and regulations relating to anti-bribery and anti-corruption including but not limited to the U.S. ForeignCorrupt Practices Act, US government health care compliance (HCC)policies, regulations and laws, US Export Administration Act of 1979 (50App. U.S.C. §2401 et. seq.) and the UK Bribery Act, as amended, and theregulations promulgated thereunder and any applicable similar laws andregulations in any other country) (collectively, the “Relevant Laws”);(ii)to have and maintain in place throughout the term of this Agreement theirown policies and procedures to ensure compliance with the Relevant Lawsand will appropriately enforce those policies and procedures; and(iii)that no employee, contractor, supplier, agent, broker, or entity will offer orpay anything of value to a public or private official intending to influence orinduce an official act or decision or to obtain an improper advantage.(b)A material breach of this Section 13.13 shall be deemed a material breach of thisAgreement. In the event of a material breach of this Section 13.13, the party not inbreach shall have the right to terminate this Agreement, without any liability to theparty in breach, with immediate effect.(c)This Agreement is made subject to any restrictions concerning the export ofproducts or technical information from the United Kingdom or other countries whichmay be imposed upon or related to Fleet or Columbia from time to time. Each partyagrees that it shall not export, directly or indirectly, any technical informationacquired from the other party under this Agreement or any products using suchtechnical information to a location or in a manner that at the time of export requiresan export licence or other governmental approval, without first obtaining the writtenconsent to do so from the appropriate agency or other governmental entity.”25.All other terms and conditions of the Existing Agreement remain in full force and effect. Except as expressly provided in thisAmendment, the Existing Agreement shall remain unmodified and is hereby ratified and affirmed. The execution, delivery, andeffectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power, orremedy of Columbia or Fleet under the Existing Agreement.26.This Amendment, together with the Existing Agreement, sets forth the entire agreement and understanding between theParties as to the subject matter hereof and thereof and merges all prior discussions and negotiations between them, andneither of the parties shall be bound by any conditions, definitions, warranties, understandings or representations withrespect to such subject matter other than as expressly provided herein and therein or as duly set forth on or subsequent tothe date hereof in writing and signed by a proper and duly authorized officer or representative of the Party to be boundthereby.27.This Amendment may be signed in counterparts, each and every one of which shall be deemed an original, notwithstandingvariations in format or file designation which may result from the electronic transmission, storage and printing of copies of thisAmendment from separate computers or printers. Executed signature pages to this Amendment may be12CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.delivered by facsimile or a portable document format (PDF) copy (including copy(ies) sent by e-mail) and all such shall bedeemed as if actual signature pages had been delivered.28.This Amendment and and any dispute or claim (including non-contractual disputes or claims) arising out of or in connectionwith it or its subject matter or formation shall be governed by and construed in accordance with the laws of England. EachParty irrevocably agrees that the English courts shall have sole and exclusive jurisdiction to settle any dispute or claim(including non-contractual disputes or claims) arising out of or in connection with this Amendment or its subject matter orformation.IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the Effective Date.COLUMBIA LABORATORIES (BERMUDA), LTD.By: /s/ Alicia Secor ____________________________Name: Alicia Secor_______________________________Title:Chief Executive Officer_______________________FLEET LABORATORIES LIMITEDBy: /s/ Tom Horner______________________________________Name: Tom Horner_________________________________________Title:Managing Director____________________________________13CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Exhibit APart 1 - Volume adjusted purchase price[]14CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Part 2 - Pricing Model[]15CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[]”. A COMPLETE VERSION OFTHIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSIONPURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATEDUNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Exhibit BColumbia Equipment[]16